Table 1.

Summary of clinical characteristics and treatment selection for NRAS-mutant, BRAF-mutant, and WT (NRAS/BRAF wild-type) cohorts

NRAS-mutant (n = 60)BRAF-mutant (n = 53)WT (n = 116)P valuea
Gender0.29
 Female21 (35)18 (34)29 (25)
 Male39 (65)35 (66)87 (75)
Age0.11
 <60 years22 (37)35 (66)47 (41)
 ≥60 years38 (63)18 (34)69 (59)
Stage0.78
 IIIc4 (7)1 (2)11 (10)
 M1a8 (13)8 (15)8 (6)
 M1b10 (17)5 (9)19 (16)
 M1c38 (63)39 (74)79 (68)
Location of primary tumor0.02
 Head and neck7 (11)8 (15)30 (26)
 Torso20 (33)22 (42)17 (15)
 Extremities20 (33)12 (23)19 (16)
 Uveal0 (0)0 (0)5 (4)
 Acral3 (5)0 (0)15 (13)
 Mucosal5 (8)0 (0)10 (9)
 Unknown5 (8)11 (21)20 (17)
LDHb
 <ULNc38 (76)20 (54)49 (65)0.07
 >ULN12 (24)17 (46)26 (35)
Mutation detected
NRASQ61R28 (47)***
NRASQ61L5 (8)**
NRASQ61K15 (25)**
NRASQ61H3 (5)**
NRASG13R3 (5)**
NRASG13D1 (2)**
NRASG13C1 (2)**
NRASG12D2 (3)**
NRASG12C2 (3)**
BRAFV600E*47 (89)*
BRAFV600K*4 (8)*
BRAFV600R*1 (2)*
BRAFV600D*1 (2)*
Institution
 VICC26 (43)29 (55)58 (50)
 MSKCC24 (41)051 (46)
 MGH10 (17)24 (45)7 (6)
Therapyc (first-line)0.89
 IL214 (23)27 (51)17 (15)
 Ipilimumab38 (63)19 (36)86 (74)
 Anti–PD-1/PD-L18 (13)7 (13)13 (11)
Therapy (second-line)0.86
 IL21 (10)2 (9)1 (4)
 Ipilimumab6 (70)13 (59)12 (52)
 Anti–PD-1/PD-L13 (20)7 (32)10 (43)
Therapy (third-line)*
 IL2000
 Ipilimumab002
 Anti–PD-1/PD-L1010

NOTE: Asterisk (*) indicates “not applicable” or “none.”

Abbreviations: LDH, lactic dehydrogenase; ULN, upper limit of normal.

  • aPearson test between NRAS and non-NRAS genotypes.

  • bBefore initiation of immune-based therapy, missing for some patients.

  • cOnly includes immune-based therapies.